vTv Therapeutics Inc. (NASDAQ:VTVT) Receives $56.67 Average PT from Analysts

Posted by Stanley Muller on Jul 31st, 2026

Shares of vTv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report) have earned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $56.6667.

Several equities analysts recently weighed in on VTVT shares. Rodman & Renshaw started coverage on vTv Therapeutics in a research report on Tuesday, June 30th. They set a “buy” rating and a $67.00 target price on the stock. BTIG Research raised their target price on shares of vTv Therapeutics from $49.00 to $57.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Wall Street Zen upgraded shares of vTv Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Zacks Research lowered shares of vTv Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, June 11th. Finally, Weiss Ratings raised shares of vTv Therapeutics from a “sell (d-)” rating to a “sell (d+)” rating in a research note on Monday, May 18th.

Check Out Our Latest Stock Analysis on VTVT

vTv Therapeutics Stock Performance

VTVT stock opened at $32.68 on Friday. The company has a 50 day moving average price of $33.43 and a two-hundred day moving average price of $34.93. The stock has a market capitalization of $128.73 million, a P/E ratio of -35.14 and a beta of 0.25. vTv Therapeutics has a one year low of $14.00 and a one year high of $44.00.

vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported $1.65 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $1.44. The business had revenue of $36.84 million for the quarter, compared to analysts’ expectations of $20.00 million. Research analysts forecast that vTv Therapeutics will post -2.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in VTVT. Goldman Sachs Group Inc. purchased a new stake in vTv Therapeutics during the fourth quarter valued at about $221,000. 683 Capital Management LLC purchased a new position in shares of vTv Therapeutics in the 4th quarter worth about $731,000. Finally, Geode Capital Management LLC raised its holdings in shares of vTv Therapeutics by 84.3% in the 4th quarter. Geode Capital Management LLC now owns 28,194 shares of the biotechnology company’s stock worth $1,128,000 after purchasing an additional 12,896 shares during the period. 17.51% of the stock is owned by hedge funds and other institutional investors.

vTv Therapeutics Company Profile

(Get Free Report)

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.